<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554552</url>
  </required_header>
  <id_info>
    <org_study_id>YY_YY1201_001/2a</org_study_id>
    <nct_id>NCT02554552</nct_id>
  </id_info>
  <brief_title>Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee</brief_title>
  <official_title>A Multicenter, Randomized, Double-blinded, Parallel, Placebo-controlled, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular YY1201 Once in the Treatment of Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blinded, parallel, placebo-controlled, phase I/IIa&#xD;
      clinical trial of YY1201 for treatment of osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      phase I/IIa clinical trial of YY1201 for treatment of osteoarthritis of the knee&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study has been withdrawn prior to enrollment.&#xD;
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of the Weight-bearing pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of the KOOS scales on the 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the rest pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motion pain (100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment (100mm-VAS) on the 4, 12 weeks after administration with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global assessment (100mm-VAS) on the 4, 12 weeks after administration</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the swelling in the knee joint from baseline to 4, 12 weeks after administration</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the tenderness on pressure in the knee joint from baseline to 4, 12 weeks after administration</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the Range Of Motion(ROM) in the knee joint on 4, 12 weeks after administration with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication count and the total amount on 4, 12 weeks</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of the Weight-bearing pain on 12 weeks in comparison with baseline</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of the OMERACT-OARSI on 12 weeks in comparison with baseline</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>YY1201 2ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY1201 2ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YY1201 3ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY1201 3ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate buffered saline 2ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 3ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate buffered saline 3ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY1201 2ml</intervention_name>
    <description>YY1201 2ml</description>
    <arm_group_label>YY1201 2ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2ml</intervention_name>
    <description>phosphate buffered saline 2ml</description>
    <arm_group_label>Placebo 2ml</arm_group_label>
    <other_name>Placebo comparator 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY1201 3ml</intervention_name>
    <description>YY1201 2ml</description>
    <arm_group_label>YY1201 3ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 3ml</intervention_name>
    <description>phosphate buffered saline 3ml</description>
    <arm_group_label>Placebo 3ml</arm_group_label>
    <other_name>Placebo comparator 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or Females 40 years and older&#xD;
&#xD;
          2. According to the clinical diagnosis standard of the American College of Rheumatology&#xD;
             (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to&#xD;
             over 3 conditions of followings.&#xD;
&#xD;
               -  Over 50 years of age&#xD;
&#xD;
               -  Less than 30 minutes of morning stiffness&#xD;
&#xD;
               -  Crepitus on active motion&#xD;
&#xD;
               -  4 bony tenderness&#xD;
&#xD;
               -  Bony enlargement&#xD;
&#xD;
               -  Nopalpable warmth of synvium&#xD;
&#xD;
          3. Within 6 months from screening visit, someone who diagnosed with Kellgren &amp; Lawrence&#xD;
             Grade I~III by the radioactive examination.&#xD;
&#xD;
          4. By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the&#xD;
             single or both sides of the osteoarthritis is over 40mm&#xD;
&#xD;
          5. Patient (No-responder) who has experienced steady pain in spite of dosing NSAIDs or&#xD;
             other pain-killers in the past.&#xD;
&#xD;
          6. Patient who can walk by themselves without helper like cane or walker etc. (If the&#xD;
             patient who has used helper routinely from previous 6 months, evaluating the patient&#xD;
             including the helper is possible. In this case, patient needs to use same helper&#xD;
             continuously by end of the clinical trial test.)&#xD;
&#xD;
          7. Patient who agrees to participate in this clinical trial by themselves.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Someone who has BMI≥32kg/m² at the screening visit.&#xD;
&#xD;
          2. Patient who has an experience dosing psychoactive drug, narcotic analgesic which can&#xD;
             have an effect on pain sense over 3 months habitually.&#xD;
&#xD;
          3. Patient who has been administrated gastrointestinal drug(for example H₂-blockers,&#xD;
             misoprostol or proton pump inhibitors) regularly, who can't stop injecting for&#xD;
             clinical study period.&#xD;
&#xD;
          4. Patient has attended abnormal values from screening test(2 times excess at upper limit&#xD;
             of the normal values at ALT, AST, BUN, Serum Creatinine).&#xD;
&#xD;
          5. Patient who has rheumarthritis or other inflammatory metabolic arthritis.&#xD;
&#xD;
          6. Patients having serious gastrointestinal, liver, renal, heart disease.&#xD;
&#xD;
          7. When the inflammatory disease is occurred on joint area to patient like septic&#xD;
             arthritis.&#xD;
&#xD;
          8. Patients having skin ailment at the injecting site of the joint region.&#xD;
&#xD;
          9. Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis&#xD;
             or systemic disease.&#xD;
&#xD;
         10. Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc&#xD;
             herniation.&#xD;
&#xD;
         11. Poly-articular patients who have suffered seriously by osteoarthritis at other parts&#xD;
             affect judge of the knee joint pain.&#xD;
&#xD;
         12. Patients who diagnosed clear interval disappearance at the knee joint by X-ray.&#xD;
&#xD;
         13. Patients who were administrated below drugs before baseline visit.&#xD;
&#xD;
               -  Patients who were injected HA at the target knee joint in recent 9 months.&#xD;
&#xD;
               -  Patients who were injected HA at other parts of the knee joint in recent 6&#xD;
                  months.&#xD;
&#xD;
               -  Patients who were injected steroids into the intra-articular knee joint.&#xD;
&#xD;
               -  Patients who were administrated steroids systemically by the oral medication&#xD;
                  (But, except inhalation)&#xD;
&#xD;
         14. Patients who have joint effusion trouble were judged as a positive by tests like&#xD;
             Patella tap test.&#xD;
&#xD;
         15. Patients who have target knee joint gotten surgical operation history including&#xD;
             Arthroscopy within past one year (In case of having other side of knee joint or hip&#xD;
             joint gotten surgical operation history, excepting the patients if there is&#xD;
             possibility which can influence the target knee joint's appraisal.&#xD;
&#xD;
         16. Patients who have an operation history about target knee joint.&#xD;
&#xD;
         17. Patients who do the height weight aerobic exercise or anaerobic exercise.&#xD;
&#xD;
         18. Patients who need to be administrated anticoagulant agent together(But, except 300mg&#xD;
             daily dose aspirin)&#xD;
&#xD;
         19. Patients who have hypersensitivity history about Investigational Product.&#xD;
&#xD;
         20. In the midst of women in their childbearing years, patients who disagree to do *&#xD;
             contraception by medically permitted method for 12 weeks from administrating&#xD;
             investigational product.&#xD;
&#xD;
             * The contraception by medically permitted method: Condom, In case of using injection&#xD;
             or insertion, In case of installing a intrauterine contraception device etc.&#xD;
&#xD;
         21. Patients who were injected other investigational product over a time within 30 days&#xD;
             before participated in this clinical trail.&#xD;
&#xD;
         22. Besides that, the patients who have difficulty to be participated in this clinical&#xD;
             trial continuously by Principle Investigator (PI)'s decision.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul-Won Ha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Department of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

